The 2026 ACC/AHA dyslipidemia guideline places greater emphasis on earlier risk assessment, PREVENT-ASCVD estimates, LDL-C and non-HDL-C goals, and selective use of Lp(a), ApoB and coronary artery calcium.

Point-of-care lipid testing can add real-time information to the existing office visit without changing its clinical purpose. With results available while the patient is still present, care teams can support a more informed discussion and determine appropriate next steps sooner.

Your Content Goes Here